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a b s t r a c t
Enterovirus 71 (EV71) is a highly infectious agent that causes hand–foot–mouth disease (HFMD) in
humans. Effective vaccination against EV71 infection is critically important, given the recent outbreak
of HFMD in the Asia-Paciﬁc region, where it has shown signiﬁcant mortality and morbidity. There is
currently no approved anti-viral therapy available to treat the disease. While several vaccine manufac-
turers are actively developing EV71 vaccines, there are no international reference standards available to
conduct quality control on EV71 vaccines or to assess the effectiveness of EV71 vaccines in immunized
populations. In the current report, antigen reference standard based on the C4 subtype of the EV71 vac-
cine strain was developed. In addition, neutralizing antibody (NTAb) reference panels were analyzed and
standards with various neutralizing titers were selected. These reference antigens were used to calibratentigen
eutralizing antibody (NTAb)
vaccine samples from several producers and found that ﬁve EV71 antigens and the national reference
standards showed good linearity and parallelism. Moreover, mice immunized with various vaccines at
doses standardizedby thesenational references showedcomparableNTAbresponses. Finally, thenational
NTAb reference panels were found to effectively reduce assay discrepancy between different labs. Taken
together, these national reference standards are highly valuable for the standardization and evaluation
of EV71 vaccines.. Introduction
Enterovirus 71 (EV71) is a member of the Picornaviridae family
nd one of the major causative agents for hand–foot–mouth dis-
ase (HFMD). EV71 has been reported to be associated with severe
iseases of the central nervous system in children less than ﬁve
ears old [1,2]. In recent years, outbreaks and epidemics caused by
V71 have occurred more frequently [3]. The prevalence of EV71
as been increasing in the Asia-Paciﬁc region after the Malaysian
V71 epidemic in 1997. Since 2007, EV71 epidemics have occurred
nChina annually. Thenumberof patientswhohavedied fromEV71
nfections in China has been increasing as follows: 126 in 2008, 353
n 2009, and 905 in 2010 [4]. The development of an effective EV71
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vaccine is of unquestionable importance, given the recurringnature
of HFMD epidemics and lack of effective anti-viral therapy.
Currently, several EV71 vaccine candidates, all of them were
inactivated whole viruses, have been developed by multiple vac-
cine companies inmainlandChina andTaiwan [5]. There are at least
three vaccines produced in mainland China and one from Taiwan
that have entered into clinical trials [6]. Unlike thepolio andﬂuvac-
cines, which have reference standards provided by theWHO, there
are no EV71 vaccines reference standards on antigen quantiﬁcation
and assessment of neutralizing antibody (NTAb) levels [7,8]. Anti-
gen content is a keyparameter for active components in the vaccine
preparations. The antigen content of all ﬁnished vaccine products
must be accurately quantiﬁed.With no universally acceptedmeth-
ods available, EV71 vaccine manufacturers have quantiﬁed the
antigen content with different ELISA kits obtained from uncertiﬁed
commercial vendors. These ELISA kits were developed using dif-
Open access under CC BY-NC-ND license.ferent acceptance criteria [9,10]. Therefore, the antigen content of
each EV71 vaccine and the dosage of each ﬁnished product vary by
company, rendering it difﬁcult to determine the vaccine dose suit-
able for clinical trials. Sowedevelopednational reference standards
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Table 1
EV71 antigen and protein content of freeze-dried reference panels (Lot: 20100701).
Lab Antigen content (KU/ml) Protein content (g/ml)
Number of tests Average (95%CI) CV (%) Number of tests Average (95%CI) CV (%)
1 10 1423.2 (1271.6–1574.8) 5.4 3 56.38 (56.04–56.72) 0.31
2 10 1494.6 (1365.1–1624.1) 4.4 3 57.69 (52.06–63.31) 4.97
3 10 1411.0 (1215.9–1606.1) 7.1 3 54.23 (51.28–57.18) 2.77
4 10 1436.8 (1232.6–1641.0) 7.2 3 57.79 (50.47–65.10) 6.46
Total 40 1441.4 (1263.6–1619.2) 6.2 12 56.52 (51.45–61.59) 4.58
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Note: Collaborative calibration of EV71 antigen content in lyophilized candidate an
ts better speciﬁcity, reproducibility, and veracity before this study. The protein co
CATM.
f EV71 antigen content and NTAb panels for the quality control
nd immunogenicity evaluation of EV71 inactivated whole virus
accines.
. Materials and methods
.1. Establishment of vaccine antigen reference standards
The following four laboratories were involved in antigen stan-
ard preparation, collaborative calibration, and stability studies:
he National Institute for the Control of Pharmaceutical and Bio-
ogical Products (Lab 1), the Institute of Medical Biology, Chinese
cademy ofMedical Sciences (Lab 2), theNational Vaccine & Serum
nstitute (Lab 3), and Sinovac Biotech Co., Ltd., Beijing (Lab 4).
.1.1. Preparation and assay of EV71 inactivated vaccine bulk
AC4 subtype EV71virus strainwas isolated in 2008 fromFuyang
n China’s Anhui Province. This virus was cultured in Vero cells,
nactivated by formalin (1:2000) and then puriﬁed in Lab 4 accord-
ng to relevant requirements speciﬁed in Chinese Pharmacopoeia. A
otal of 500g vaccine bulk (Lot: H07-0812-022) was prepared. The
esidual Vero cell DNA, residual Vero cell proteins and BSA in the
reparation were evaluated and found to have met the speciﬁca-
ions [11,12]. Residual Vero cell protein was 0.32g/ml, residual
ero cell DNA was <2ng/ml, BSA was 7.1ng/ml (Supplementary
able 1). EV71 antigen contentwas 20,744.6KU/ml (KU: Lab 4 anti-
en unit), which was determined by Lab 4 ELISA kits. TOSHO TSK
6000PWXLgelﬁltration chromatographywasused forHPLCanal-
sis on the purity of this preparation.
.1.2. Preparation of lyophilized antigen reference standards
Veriﬁed stabilizer and diluents for lyophilization process were
dded to the bulk solution. The bulk solution was diluted 7.43
imes, aliquoted at 0.6ml/vial and then lyophilized for storage (Lot:
0100701).
.1.3. Collaborative calibration of antigen content in lyophilized
ntigen reference standard
Three different EV71 antigen quantitative assay kits were com-
ared by four collaborating labs before the commencement of this
tudy. EV71 antigen quantitative assay kit (EL-4 kit) from Lab 4
able 2
nalysis of EV71 antigen standard.
Lab Number of tests Linear working range (U/ml) Slope rate
Average 95% C
2 7 5–80 0.0138 −0.01
3 9 1.25–80 0.0170 0.01
4 10 5–80 50.097 41.04
5 4 0.125–4 0.6378 0.61
6 8 2.5–40 0.052 0.04
ote: EV71 antigen standard was analyzed using ﬁve kinds of ELISA kits from Labs 2–6. Thstandards was performed in four separate labs by EL-4 kits which was selected for
in H07-0812-022 vaccine bulk solution was tested in four separate labs by Micro
was selected for its better speciﬁcity, reproducibility, and verac-
ity [9]. Antigen content in EV71 antigen reference standard was
assayed ten consecutive times by each laboratory. To reduce intra-
and inter-lab discrepancy, strict adherence to the same SOP was
followed in all four labs. Antigen content of EV71 antigen national
standards were deﬁned based on results from all four labs.
2.1.4. Collaborative assay of protein content in lyophilized
antigen standards
Protein content was assayed three times at each laboratory
using Micro BCATM Protein Assay Kits (Thermo Scientiﬁc, Lot:
LG146257). H07-0812-022 bulk solution was assayed before addi-
tion of the stabilizer.
2.1.5. Applicability of EV71 antigen standards
Reference standards were distributed to ﬁve participating lab-
oratories. EV71 antigen contents of ﬁve EV71 inactivated vaccine
antigenswere testedwith reference standards in ﬁve Labs by ELISA
kits made by different manufacturers and used in these partic-
ipating laboratories (Supplementary Table 2). Linear regression
coefﬁcients and linear ranges of the candidate standards were ana-
lyzed. Parallelism was also analyzed.
2.2. Reference standards for neutralizing antibodies
The following laboratorieswere involved in the preparation and
calibration of reference standards for levels of NTAb: the National
Institute for the Control of Pharmaceutical and Biological Products
(Lab 1), Institute of Medical Biology, Chinese Academy of Medical
Sciences (Lab2),NationalVaccine&SerumInstitute (Lab3), Sinovac
Biotech Co., Ltd., Beijing (Lab 4), andHualan Biological Engineering,
Inc. (Lab 5).
2.2.1. Detection of EV71 or Coxsackievirus A16 (CA16)
neutralizing antibodies
The microplate cytopathic effect method (CPE method) was
used to analyze EV71 (or CA16) NTAb titer [13,14]. Serum was
inactivated for 30min at 56 ◦C. Samples were serially diluted
from 1:8 to 1:2048, mixing with equal volumes of 100 TCID50
EV71 or CA16 viruses. After incubation at 37 ◦C for 2h in 96-well
Intercept R2
.I. Average 95% C.I. Average CV (%)
04 to 0.0379 0.1126 0.0574 to 0.1677 0.9897 0.26
20 to 0.0221 0.109 0.0073 to 0.2107 0.9859 1.19
38 to 59.1500 −2.459 −4.8424 to −0.0759 0.9982 0.21
37 to 0.6619 0.0796 0.0593 to 0.1000 0.9985 0.07
42 to 0.0598 0.008 −0.0371 to 0.0531 0.9985 0.10
e dates are the mean values of 4–10 independent experimental results in Labs 2–6.
9 ine 29
p
t
v
f
w
a
t
o
N
2
5
t
a
E
o
N
A
m
p
w
w
p
2
s
l
c
−
f
s
f
2
d
p
2
s
g
s
G
C
b
a
b
w
s
s
E
b
a
2
(
p
v
i
q670 Z. Liang et al. / Vacc
lates, rhabdomyosarcoma (RD) cell suspension (ﬁnal concentra-
ion:1–2×105 cells/ml)wasadded. Cell control, serumcontrol, and
irus control were set on each plate, and virus backdrops were set
or each test. Tests were considered successful if backdrop results
ere32–320TCID50/well. Theywere thenplaced inaCO2 incubator
t 35 ◦C for 7 days. CPEswere observed bymicroscopy. Neutralizing
iterswere deﬁned as the highest dilution capable of inhibiting 50%
f the CPEs. Neutralization titers ≥1:8 were considered positive for
TAb.
.2.2. Screening of candidate reference standards for NTAb
Fifty plasma samples from healthy individuals (provided by Lab
) with glutamic-pyruvic transaminase (ALT) <25U and conﬁrmed
o be negative for HBsAg, HIV antibody, HCV antibody, and syphilis
ntibody (tests made by kits from Abbot Inc., US) were assayed for
V71–NTAb titers. Eight candidate standards with different levels
f neutralizing activities (Nos. J4, J10, J15, J16, N3, N12, N25, and
30) were chosen from these ﬁfty samples (Supplementary Fig. 2).
mong them, four plasmas (Nos. J4, J10, J15, and J16) were deter-
ined to be negative EV71–NTAb standards and two EV71–NTAb
lasmas with titer >1:100 (Nos. N3 and N30) were selected as
eak positive EV71–NTAb standards. Two EV71–NTAb plasmas
ith titers >1:500 (Nos. N12 and N25) were selected as strong
ositive EV71–NTAb standards.
.2.3. Preparation and distribution of EV71–NTAb candidate
tandards
Eight EV71–NTAb standards were lyophilized by a vacuum
yophilizer according to instructions speciﬁed in Chinese Pharma-
opoeia, 3rd edition [11,12]. Lyophilized standards were kept at
20 ◦C before use. Samples were blinded and distributed by Lab 1
or collaborative calibration. Samples were reconstituted in 0.2ml
terile water. Analysis was carried out according to SOPs speciﬁc
or this collaborative calibration.
.2.4. Detection of CA16–NTAb in candidate standards
Three independent assays were performed by Lab 1 to
etermine CA16–NTAb titer in candidate standards. These were
erformed using the G-10 virus strain of CA16 provided by Lab 2.
.2.5. Collaborative calibration of EV71–NTAb in candidate
tandards
Eight EV71 virus strains (1 strain from genotype A, 1 strain from
enotype B3 and 6 strains from subtype C4a) were included in this
tudy. BrCr (type A) was isolated from California (US) in 1969 [15].
enotype B3 strain was adapted to infect mouse brains [16]. Six
4 strains were isolated from an HFMD epidemic region in China
etween 2007 and 2009. These strains were ﬁrst veriﬁed by EV71
nd CA16 NTAb standard serum and speciﬁc PCR. Virus titers were
etween 106.8 and 107.9 TCID50/ml. Except for genotypes A and B,
hich are genetically distant, VP1 from six strains of C4a subtype
howed over 92% homology. The passage background of eight virus
trains was clearly documented (Supplementary Fig. 3).
Every lab used 1–3 EV71 virus strains (Supplementary Table 3).
V71-neutralizing antibodies were assayed ten consecutive times
yeach laboratory. To reduce intra- and inter-labdiscrepancy, strict
dherence to the same SOP was followed in all four labs.
.2.6. Deﬁnition of EV71–NTAb standards and quality control
QC) sera
Calibration data from all labs were collected by Lab 1. One sam-
le was screened to determine quantitative standards. To further
alidate the accuracy of EV71–NTAbanalysis, negative,weakly pos-
tive and strongly positive sera were screened. These became the
uality control sera.(2011) 9668–9674
2.2.7. Application of NTAb standards and QC serum
Three Labs (except Labs 2 and 5) were involved in the applica-
tion of NTAb standards and QC serum with a common virus strain
(A-01) distributed by Lab 1 (Supplementary Table 3). Seventeen
serum samples from healthy people were assayed by three Labs.
Test results were analyzed by Lab 1. According to the titer of quan-
titative standard, the titers of samples were standardized as NTAb
units (U/ml). Deviation in NTAb titers before and after standardiza-
tion of seventeen serum samples in different labs was analyzed.
2.3. Evaluation of vaccines normalized by national reference
standards
2.3.1. EV71 vaccines with equivalent antigen content
Three batches of EV71 vaccine and eachbulk solution from three
different companies were selected. Based on EV71 antigen stan-
dards (1600U/ml), the EV71 antigen content of each bulk solution
was tested using Lab 4 EV71 antigen quantitative assay kit by the
double parallel line method. Three batches of vaccine with equiva-
lent antigen content (B1-1, B2-1, and B3-1: 324U/ml) were diluted
with 1.0mg/ml aluminum salt buffer.
2.3.2. Animals and animal immunization
Female ICR mice aged 4–6 weeks (provided by Vital River Labo-
ratories) were randomly divided into four groups of 15 mice each.
Each mouse was injected intraperitoneally (i.p.) with 162U/0.5ml
of EV71 vaccine (B1-1, B2-1, or B3-1). Aluminum salt buffer served
as a control. Blood samples were collected three weeks after pri-
mary immunization. Serum was kept at −20 ◦C for analysis.
2.3.3. EV71–NTAb standards
EV71–NTAb standards (1000U/ml and three QC) and EV71 anti-
gen standards (1600U/ml) were provided by Lab 1.
2.4. Statistics
Antigen contentwas analyzed bymultiple parallel line compari-
son. The statistical validity of parallelism and linearity of the assays
was assessed by analysis of variance tests. Parallelism was further
assessed by comparing estimates of the slopes of the response lines
across all assays.
The neutralization titer of EV71was deﬁned as the highest dilu-
tion capable of inhibiting 50% of CPE. Neutralization titers ≥1:8
were considered positive for NTAb. Seropositive rates were com-
pared by chi-square test. Laboratory means of neutralization titer
estimateswere calculatedasgeometricmean titers (GMTs) for indi-
vidual assay estimates. For the statistical analysis of GMTs, the
data were transformed using the log10 of the original values and
then analyzed with SPSS 10.0 software. This transformation was
effective in stabilizing the dispersion and rendered the variances
independent of the means. If the titers of neutralizing antibodies
were negative, then they were assumed to be 1:4 for calculation
purposes. A paired t-test was performed with P<0.05 considered
statistically signiﬁcant.
3. Results
3.1. Establishment of EV71 antigen standards
An EV71 antigen standard preparation H07-0812-022 was pro-
duced from a C4 subtype EV71 virus strain isolated in 2008 from
Fuyang in China’s Anhui Province. The virus was cultured in Vero
cells and then inactivated by formalin (1:2000) and puriﬁed using
column chromatography. A total of 500g vaccine bulk was pro-
duced. HPLC results showed that EV71 virus particles appeared
at the 12.5-min peak with an EV71 antigen purity of 98.68%
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Table 3
EV71–NTAb and CA16–NTAb of 8 candidate standards.
Candidate EV71–NTAb CA16–NTAb
Anti-EV71 GMT 95% C.I. CV (%) Anti-CA16 GMT 95% C.I. CV (%)
J4 1:6.5 1:4.5–1:9.5 23.8 1:39 1:3–1:515 7.8
J10 1:4.3 1:3.9–1:4.7 7.5 1:9 1:5–1:16 10.6
J15 1:6.8 1:4.5–1:10.4 26.4 1:314 1:24–1:4121 5.0
J16 1:7.1 1:4.9–1:10.2 22.4 1:4 1:4–1:4 0
N3 1:120.7 1:87.8–1:165.9 7.9 1:55 1:17–1:179 11.9
N12 1:712.5 1:573.1–1:885.7 4.0 1:5 1:2–1:14 24.7
N25 1:1023.0 1:887.5–1:1179.0 2.5 1:39 1:3–1:515 7.8
N30 1:181.3 1:97.6–1:336.9 14.2 1:128 1:128–1:128 0
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iote: EV71-neutralizing antibodies from eight candidate alternative standards wer
aboratories. Each sample was tested 10 times. The data in the table represent the
ested with CA16 strain (G10) in Lab 1. Each sample was tested three times. Results
Supplementary Fig. 1) and this bulk material was used to prepare
yophilized EV71 antigen reference standards.
A collaborative calibration of EV71 antigen content in
yophilized EV71 antigen standards was performed in four differ-
nt labs using the EL-4 kits (Table 1). The means of EV71 antigen
ontent was 1441.4KU/ml which is close to the theoretical anti-
en content of 1396.0KU/ml (20,744.6/7.43/1.2×0.6). The overall
ariance coefﬁcient was 6.2% (the CV from each lab was 5.4%, 4.4%,
.1%, and 7.2%, respectively).
The protein content in H07-0812-022 vaccine bulk solutionwas
etermined to be 56.52g/ml by Micro BCATM Kit, with a CV of
.6% (Table 1). The CV from each lab was 0.3%, 5.0%, 2.8%, and
.5%, respectively. Considering thedilution factors inpreparationof
ulk solution, total protein content in lyophilized candidate antigen
tandards was determined to be 3.80g/ml (56.52/7.43/1.2×0.6).
Based on results from the above calibration studies, the national
ntigen standard was deﬁned as 1600U/ml (EV71 antigen unit).
rotein content in this batch of reference standardswas 3.80g/ml
ith a speciﬁc activity of 421.1U/g.
.2. Applicability of national antigen standards
In order to ensure the reference standards can be used in dif-
erent laboratories with different detection kits, this standard was
ested using different EV71-ELISA antigen detection kits in ﬁve
aboratories. The linear range for each kit was 5–80, 1.25–80,
–80, 0.125–4, and 2.5–40U/ml, respectively. Mean R2 valueswere
.9897, 0.9859, 0.9982, 0.9985, and 0.9985, respectively (Table 2).
he above ﬁve EV71 antigen tests showed good parallelism and
inear relationships with reference standards on each kit (P>0.05),
uggesting that the candidate antigen standards possessed good
pplicability (Fig. 1).
.3. Establishment and deﬁnition of EV71–NTAb standards
Eight EV71virus strainswereused in four collaborating labs. Ten
ndependent assays of EV71–NTAb were performed for the eight
andidate standards. Four negative standards showed NTAb GMTs
n the ranges of 1:4–1:12, showing that the NTAb CV of each strain
as within 27%. Four positive standards showed NTAb GMTs in the
ange of 1:80–1:1200, showing that the NTAb CV of each strainwas
ithin 15% (Table 3).
Based on EV71–NTAb GMTs of candidate standards, CV values
Table 3) and CA16–NTAb GMTs (Table 3), the N12 lyophilized ref-
rence standard (EV71–NTAb GMTs 1:712.5, CV 4.0%, CA16–NTAb
egative)was chosen as the EV71–NTAb standard. The EV71–NTAb
ontent of N12 was set as 1000 EV71U/ml (NTAb units).
To further validate accuracy of EV71–NTAb analysis, based on
he establishment of EV71–NTAb standards, negative, weakly pos-
tive, and strongly positive QC sera were screened from eightpendently tested with each of the eight EV71 viral strains in the four participating
s of 80 NTAb tests. CA16–NTAbs from eight candidate alternative standards were
considered negative if NTAb titer <1:8. GMTs were calculated as 1:4.
candidate standards according to the results of NTAb GMTs and
CVs of different strains.
Negative QC serum: four negative candidates were tested in
different labs using different strains. These tests showed that J10
had the lowest GMT (1:4.3) and CV (7.5%). J10 was chosen as the
negative EV71–NTAb QC serum (Table 3).
Weakly positive QC serum: GMTs of antibodies for two weakly
positive candidates, N3 and N30, were found to be 1:120.7 and
1:181.3. The CVs were found to be 7.9% and 14.2% (Table 3). The
CA16 antibody GMTs of N3 and N30 were 1:55 and 1:128. N3 was
chosen as the weakly positive EV71–NTAb QC serum because it
showed the lowest CV and lowest level of CA16–NTAb.
Strongly positive QC serum: Two strongly positive candidates,
N12 and N25, both showed high GMTs of EV71–NTAb and low CVs
(Table 3). N12was negative for CA16–NTAb. N12was chosen as the
strongly positive EV71–NTAb QC serum.
3.4. Applicability of standards and QC sera
EV71–NTAb standards, QC sera, and seventeen serum samples
from healthy individuals were assayed in Labs 1, 3, and 4 using
the A-01 strain. NTAb titer in each sample was standardized to
antibody units (U/ml) based on the neutralizing titer of the N12
standard (Table 4). CV mean values and Max–Min deviations were
19.2% and 5.6 times before standardization. CV mean values and
Max–Min deviationswere 8.2% and 2.4 times after standardization.
Mean values and deviations were reduced by 11.0% and 3.2 times,
on average. Analysis of variance showed that there was signiﬁcant
difference between before and after standardization.
3.5. Application of EV71 standards in vaccine immunogenicity
comparisons
As shown in Table 5, vaccines from three companies were stan-
dardized to equal antigen content. A 162U/0.5ml dose of vaccine
wasused to immunize eachmouse in three groupsofmice. Twenty-
one days after the ﬁrst dose, the positiveNTAb ratewas 76.7–83.3%.
The NTAb was 1:33.0–1:53.6 (42.9–69.8U/ml). No signiﬁcant dif-
ferencewas found for the rates and titers of positiveNTAb (P>0.05),
indicating that single injections in mice with standardized doses
of vaccines from different companies induced comparable NTAb
responses.
4. Discussion
HFMD is a serious public health concern in the Asia-Paciﬁc
region, especially in China and Southeast Asia. An effective EV71
vaccine will be an efﬁcient way of controlling HFMD. Vaccines in
development include the following: whole-virus and inactivated
vaccines, recombinant VP1 protein vaccines, VLPs, VP1 synthetic
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Fig. 1. Application of EV71 antigen standard. Note: EV71 antigen content of ﬁve kinds EV71 inactivated vaccine antigen from Labs 2 to 6, was ascertained using ﬁve kinds
of ELISA kits from ﬁve participants. Parallelism and linearity were analyzed by multiple parallel line comparison. The statistical validity of the parallelism and linearity of
the assays was assessed by analysis of variance tests. (A) Lab 2: parallel F=0.06 (P>0.05), linearity F=3.04 (P>0.05);(B) Lab 3: parallel F=0.56 (P>0.05), linearity F=2.50
(P>0.05); (C) Lab 4: parallel F=1.20 (P>0.05), linearity F=0.18 (P>0.05); (D) Lab 5: parallel F=1.33 (P>0.05), linearity F=2.62 (P>0.05); (E) Lab 6: parallel F=1.89 (P>0.05),
linearity F=0.45, (P>0.05).
Table 4
EV71–NTAb tested before and after standardization in different laboratories.
Sample ID Lab Before standardization (neutralizing titer) After standardization (U/ml)a Reduced
GMTs CV (%) Max–Min multiple
difference
GMTs CV (%) Max–Min multiple
difference
CV (%) Max–Min multiple
difference
Y1 3 1:140.7 20.2 7.2 445.1 7.3 2.3 12.9 4.9
Y2 3 1:66.0 11.3 2.4 208.9 12.6 3.7 −1.3 −1.4
Y3 3 1:183.5 10.8 2.8 580.6 3.9 1.6 6.9 1.1
Y4 3 1:72.8 24.4 8.0 230.4 9.3 2.6 15.1 5.4
Y5 3 1:199.7 23.7 10.7 631.9 7.5 2.6 16.2 8.1
Y6 3 1:46.4 16.8 3.6 146.9 8.3 2.1 8.4 1.6
Y7 3 1:50.7 25.5 6.1 160.4 5.0 1.7 20.5 4.4
Y8 3 1:55.7 18.3 4.0 176.2 13.4 3.5 5.0 0.6
Y9 3 1:62.2 31.1 12.8 196.9 13.2 3.5 17.9 9.3
Y10 3 1:67.8 19.3 5.0 214.7 10.6 3.0 8.8 2.0
Y11 3 1:132.0 18.1 5.2 417.6 3.5 1.5 14.6 3.7
Y12 3 1:62.3 14.6 3.2 197.2 5.9 1.8 8.7 1.4
Y13 3 1:95.8 21.4 6.4 303.2 5.7 1.8 15.7 4.7
Y14 3 1:30.6 22.2 4.4 96.9 13.4 3.1 8.8 1.3
Y15 3 1:255.5 10.8 2.9 808.5 2.8 1.4 8.0 1.5
Y16 3 1:112.4 16.5 4.6 355.6 5.4 1.9 11.1 2.7
Y17 3 1:53.4 22.1 5.7 168.9 11.9 3.4 10.2 2.4
Mean 3 1:99.2 19.2 5.6 314.1 8.2 2.4 11.0 3.2
Note: Seventeen serum samples from healthy volunteers were tested by EV71(A-01) stain along with NTAb standards and QC serum in Labs 1, 3, and 4. The titers of the
samples were standardized as NTAb units according to neutralizing standards (U/ml).
a After the alternative standards were applied, signiﬁcant differences in CV (F=81.87, P<0.05) and Max–Min multiple difference (F=39.50, P<0.05) were observed.
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Table 5
The positive rate and GMT of EV71–NTAb immunized with equivalent amounts of EV71 vaccine.
B1-1 B2-1 B3-1
Positive rate (%)a 80.0 76.7 83.3
GMT (95%CI)b
Neutralization titer 1:45.3 (1:28.1–1:73.0) 1:33.0 (1:20.7–1:52.6) 1:53.6 (1:34.9–1:82.3)
Neutralization antibody (U/ml) 59.0 (36.6–95.1) 42.9 (26.9–68.5) 69.8 (45.5–107.1)
Note: The sera were collected three weeks after female mice, 4–6 weeks old, were vaccinated with 162U/0.5ml of EV71 vaccine (B1-1, B2-1, B3-1). EV71–NTAb levels were
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[easured by CPE on RD cells. The data are mean values of two independent experim
a F=0.42, P>0.05.
b P>0.05.
eptide vaccines, and VP1 DNA vaccines [17–22]. The protective
ffects of various types of vaccines in animals were demonstrated
y the results of an inactivated whole-virus vaccine study [23].
n China, three companies have completed preclinical studies on
heir EV71 inactivated vaccines, all of which have been approved
or clinical trials.
The determination of EV71 vaccine antigen content is critical
or the optimization of the vaccine manufacturing process, accu-
ate calculation of vaccine antigen recovery rate, establishment of
C standards for antigen content, deﬁnition of ranges and speciﬁ-
ations of speciﬁc activities for vaccine strains, bulks and ﬁnished
roducts, and determination of dosage for ﬁnished vaccine prod-
cts. Different companies in China use different kits and reference
tandards. Dosage units for ﬁnished products are not compara-
le between various vaccines because each producer uses its own
LISAunit. To standardize assays for antigen content determination
nd intended dosage for clinical use, national standards for EV71
accine antigen content analysis should be established.
A batch of EV71 antigen reference standard was developed
eeting the requirements of the WHO and Chinese Pharmacopoeia
egarding the preparation of national standards and the calibration
f biological products. For the representativity of EV71 antigen ref-
rence standard, we had compared antigenicity of EV71 antigen
tandard with EV71 bulks from three manufacturers. The results
emonstrated that EV71 antigen reference standard has the good
arallelism and linearity for different antigens mentioned above
Supplementary Table 4). Also, we performed recovery assay on
ve EV71 bulks and three ﬁnal vaccine products from different
ompanies using the standard in EL-4 kits. The recovery rates
ere 76–118% and 86–106% in bulks and ﬁnal vaccines, respec-
ively. The results indicated that the reference standard could be
atisfactorily applied to the analyses of different antigens. To pre-
are EV71 antigen reference standard with good stability, we used
yophilized technique in this standard and compared the lyophili-
ation’s effect on the immunogenicity and antigenicity of EV71
tandard. The EV71 antigen content before and after lyophilization
1441.4KU/ml, 1396.0KU/ml)was basically consistent andpositive
onversion rate (>1:8) of NTAb was all 90% in mice immunized by
V71 standard before and after lyophilization. This showed that the
ntigenicity and the immunogenicity of lyophilized EV71 standard
ere not changed. It can be used to accurately measure antigen
ontent in EV71 inactivated vaccines. Based on results of a col-
aborative calibration project, the antigen content in the national
ntigen standard was determined to be 1600U/ml (EV71 antigen
nits). For applicability of standard, the standardwas distributed to
ve separate labs. Results showed that antigens could be accurately
easured within the linear range of kits from all ﬁve companies.
Microplate cytopathic effect assay is a common means of
V71–NTAb detection. As a result of Yu et al. using neonatal mater-
al mouse antibody and EV71–NTAb to passively immunize baby
ice, the protective effects of EV71–NTAb against virus were ver-
ﬁed [17,19,24]. Ever since, EV71–NTAb has been widely used
n EV71 vaccine development as an indicator of immunogenicity
19,22,25]..
As EV71 vaccine development has progressed, more focus
has been put on the standardization of EV71–NTAb analysis.
Some studies have suggested that differences in antigenicity exist
among different genotypes of EV71 strains, though no differ-
ence had been seen between different subtypes within same
genotype [23]. In a cross-neutralization study by Sanden et al.,
B0, B1, B2, C1, and C2 strains were used to cross-react with
B2- and C1-immunized rabbit sera, it was shown that B2 sera
could not neutralize C strain, but C1 sera could neutralize B
strain [26]. Different genotype strains were tested in neutralizing
assays with marmoset sera immunized with EV71 type A atten-
uated strain [27]. The neutralizing activity was found to be as
follows:BrCr-TR(A) >Nagoya(B1)>75-Yamagata-2003(C4) >1530-
Yamagata-2003(C4) and 2399-Yamagata-2003(C4) >C7-Osaka(B4)
and 1095 (C2). Neutralization titers of B4 and C2 were only 1.6%
(1/64) those of type A. Six subtypes of strains B and C were tested
with guinea pig sera immunized with B2 and C1 [28]. Results
showed that the differences between the neutralizing titers of
various subtypes could reach a factor of ten. The above ﬁnding sug-
gested that strains with different genotypes and strains with same
genotype but different origins could affect the results of NTAb anal-
ysis. Standards for EV71–NTAb need to be developed to ensure the
accuracy and comparability of assay data. For the representativ-
ity of NTAb reference standards, we collected plasma from healthy
adults who were naturally infected by EV71 as the source of NTAb
reference standards. Then, eight candidate standards with differ-
ent EV71 neutralizing titers were selected by screening from ﬁfty
plasma samples, aliquoted and lyophilized. Collaborative calibra-
tion was carried out in four labs. A ﬁrst ever EV71–NTAb standard
was established. Each parameter met WHO and Chinese Pharma-
copoeia requirements. Based on collaborative calibration results,
the EV71–NTAb titer of theN12 standardwas deﬁned as 1000U/ml.
One negative standard, J10, one weakly positive standard, N3, and
one strongly positive standard, N12, made up a QC serum panel for
antibody analysis. This panel was adapted from that used in polio
virus standard antibodyanalysis [29]. QCantisera repeatswereper-
formed for each strain. The upper and lower limits of the detection
rangeswere deﬁned using themedian and four times the deviation
of the antibody GMTs of each strain. In practice, assuming that all
three QC sera were valid, NTAb GMTswere converted to U/ml from
titers based on deﬁned standards (N12).
In initial applications, a common strain distributed by Lab 1was
used in three different labs. Seventeen serum samples fromhealthy
peoplewere testedwith standards andQC sera. The results showed
that the average of CV andMax–Min deviation were reduced 11.0%
and 3.2 times after standardization. This suggests that the appli-
cation of deﬁned standards could reduce discrepancies between
analyses performed in different labs. It would facilitate the accu-
racy and comparability of EV71–NTAb detection and contribute to
the evaluation of vaccine immunogenicity.First-generation national vaccine antigen standards and NTAb
standards were approved by the Expert Committee of China for
Standards (2010 No. 0023; 0024). These standards were applied to
EV71 vaccine development in China, including their use as parts
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f the QC process for vaccine manufacturing, packaging of semi-
nished and ﬁnished products, and determination of dosage. These
lso included standards for the evaluation of immunogenicity for
reclinical studies and provided a platform for standardization of
nalysis of clinical vaccine samples in the near future.
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